Quick Answer
Zomedica Corp. reported Net Income Loss of -$81.86 million for the year ending 2025.
- Zomedica Corp. showed a decrease of -74.2% in Net Income Loss from 2024 to 2025.
- This data is from Zomedica Corp.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$1.83 million | Q2 2017: -$1.59 million | Q3 2017: -$2.08 million | Q1 2018: -$2.17 million | Q2 2018: -$4.14 million | Q3 2018: -$1.91 million | Q1 2019: -$11.68 million | Q2 2019: -$2.40 million | Q3 2019: -$2.85 million | Q1 2020: -$2.45 million | Q2 2020: -$5.31 million | Q3 2020: -$4.98 million | Q1 2021: -$4.04 million | Q2 2021: -$4.71 million | Q3 2021: -$6.35 million | Q1 2022: -$3.94 million | Q2 2022: -$5.27 million | Q3 2022: -$5.00 million | Q1 2023: -$6.39 million | Q2 2023: -$5.25 million | Q3 2023: -$491.0 thousand | Q1 2024: -$9.16 million | Q2 2024: -$23.93 million | Q3 2024: -$6.70 million | Q1 2025: -$63.81 million | Q2 2025: -$7.40 million | Q3 2025: -$6.12 million.
- Over the full 10 years of available data (2016 to 2025), Zomedica Corp.'s Net Income Loss has declined by 1,326.0%.
- Historical annual values: Fiscal year 2025: -$81.86 million | Fiscal year 2024: -$46.98 million | Fiscal year 2023: -$34.53 million | Fiscal year 2022: -$17.02 million | Fiscal year 2021: -$18.38 million | Fiscal year 2020: -$16.91 million | Fiscal year 2019: -$19.78 million | Fiscal year 2018: -$16.65 million | Fiscal year 2017: -$8.07 million | Fiscal year 2016: -$5.74 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: